Genistein Mediated Molecular Pharmacology, Cell-Specific Anti-Breast Cancer Mechanism with Synergistic Effect and in silico Safety Measurement

  title={Genistein Mediated Molecular Pharmacology, Cell-Specific Anti-Breast Cancer Mechanism with Synergistic Effect and in silico Safety Measurement},
  author={Md Mahmodul Hasan Sohel and Partha Biswas and Md. Al Amin and Dipta Dey and Habiba Sultana and Suraiya Aktar and Md. Sharif Khan and Md. Arju Hossain and Priyanka Paul and Nurul M Islam and M. Rahman and Bonglee Kim and Abdullah Al Mamun},
Breast cancer (BC) is the most common type of cancer in both men and women alike, but it is more prevalent in women. Natural compounds that can modulate the oncogenic process can be considered a significant anti-cancer agent for treating BC. These natural compounds are more effective than synthetic drugs, which have profound side effects on the normal cell and resistance to cancer cells. Genistein is a type of dietary phytoestrogen included in the flavonoid group with a similar structure of… 

Pharmacological Properties to Pharmacological Insight of Sesamin in Breast Cancer Treatment: A Literature-Based Review Study

It is summarized that this phytoestrogen suppressed NF-κB, STAT, MAPK, and PIK/AKT signaling pathways and activated some tumor suppressor protein in numerous breast cancer models and exhibited promising pharmacokinetics properties with less toxicity in the bodies.

Plants as a Source of Anticancer Agents: From Bench to Bedside

The anticancer activities of ten natural products extracted from plants are discussed, and the majority of these products inhibit cancer by targeting multiple cancer hallmarks, and many of these chemicals have reached clinical applications.



Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro.

The results reveal that genistein is unique among the flavonoids tested, in that it has potent estrogen agonist and cell growth-inhibitory actions over a physiologically relevant concentration range.

Effective chemopreventive activity of genistein against human breast cancer cells.

The results suggest that genistein could be of therapeutic value in preventing human breast cancer.

The anticancer activity of genistein is increased in estrogen receptor beta 1-positive breast cancer cells

The data indicated that ERβ1 increased the anticancer efficacy of GEN in MCF-7 cells by affecting cell cycle transition, which could be a potential therapeutic agent for ER β1-positive cancer.

Potent genistein derivatives as inhibitors of estrogen receptor alpha-positive breast cancer

Seven structurally modified derivatives of Genistein are synthesized based on the structural requirements for an optimal anti-cancer effect and it is noticed that at IC 50 concentrations, the MA-6, MA-8 and MA-19Genistein derivatives induced apoptosis, inhibited ER-α messenger RNA expression and increased the ratio of ER-β to ER- α levels in a manner comparable to the parent compound GenisteIn.

Concentration-dependent effects of genistein on global gene expression in MCF-7 breast cancer cells: an oligo microarray study

Findings provide evidence for a molecular signature of genistein’s effects in MCF-7 cells and lay the foundation for elucidating the mechanisms of Genistein's biological impact in breast cancer cells.

Genistein inversely affects tubulin-binding agent-induced apoptosis in human breast cancer cells.

Inhibitory actions of genistein in human breast cancer (MCF-7) cells.

Genistein in the Presence of 17β-Estradiol Inhibits Proliferation of ERβ Breast Cancer Cells

Genistein is suggested to be useful as a chemotherapeutic agent in premenopausal women with breast cancer of the ERα-negative and ERβ-positive type and in cells with ERβ alone, genistein most likely acts as an antiestrogen.

Additive effects of trastuzumab and genistein on human breast cancer cells

Genistein significantly enhanced the antitumoral effect of trastuzumab on BT-474 breast cancer cells in vitro, and the relevance of these data particularly for women with HER2-overexpressing and ER&agr;/&bgr;-positive breast cancer has to be verified in animal or clinical studies.